Telehealth & Digital Health

Swisslog Healthcare appoints Maria Garces from competitor Omnicell as VP, signaling an aggressive push to innovate and dominate the health tech market.

Researchers at Kanazawa University have developed engineered nanoparticles that can reprogram rogue immune cells, offering a targeted therapy for autoimmune diseases.

A Minnesota startup has secured major funding to advance its bioelectronic device aimed at the brain's waste clearance system for treating CNS disorders.

A new report projects a staggering $47T cost from chronic illness by 2039. Experts say prevention and innovation could save trillions and 13.5M lives.

The biotech upstart will present a bold pipeline, including a head-to-head trial against a market leader and a first-in-class autoimmune eye disease therapy.

Johnson & Johnson's TRUFILL n-BCA gains FDA approval for chronic subdural hematoma, offering a minimally invasive option to curb high rates of recurrence.

With trial data showing an average 23% body weight loss, Novo Nordisk's new combination drug CagriSema could usher in a powerful new era for medicine.

Pharma giant GSK partners with biotech CAMP4, leveraging novel RNA-boosting tech to develop new therapies for neurodegenerative and kidney diseases.

A new FDA approval for an EGFR-mutated lung cancer therapy cuts treatment from hours to minutes, offering new hope and convenience for thousands of patients.

The neuro-focused biotech just acquired a late-stage cancer drug, securing massive funding. Is this a brilliant diversification or a high-stakes gamble?

An international expert panel endorses an advanced wound therapy, potentially revolutionizing patient recovery and boosting a key player in the med-tech market.

Incyte's Minjuvi, a first-of-its-kind immunotherapy, gains EC approval for follicular lymphoma, offering patients a powerful new chemo-free option.

A key trial update de-risks Tenax Therapeutics' pivotal study for a novel heart failure therapy, boosting confidence in its path to market.

A Phase 1 trial for Moleculin's WP1066 shows encouraging safety and anti-tumor activity for children with deadly brain tumors like DIPG.

A new once-monthly, self-injected cholesterol drug gets FDA nod, offering more convenience and setting the stage for a major market push in China.

Zephyrus Innovations just got FDA clearance for VaporShield, a device protecting nurses from drug exposure. It’s a story of safety, market disruption, and efficiency.

An Indiana biotech prepares for biotech's biggest stage, showcasing a pipeline that offers new hope for chronic endocrine and metabolic disorders.

As Spruce Biosciences preps its rare disease drug for FDA review, the addition of a commercial veteran signals a high-stakes shift from R&D to market.

A new drug for a leading cause of blindness missed its primary goal, yet its unique ability to improve vision offers new hope for millions of patients.

A positive EU opinion for Sobi's Aspaveli could bring the first-ever targeted treatment for two rare kidney diseases, shaking up a market desperate for innovation.